Mitral regurgitation (MR) severity is an important determinant of symptom status and
prognosis in heart failure with reduced ejection fraction (HFrEF). Functional MR is frequently …

Purpose Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular
mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily …

Few studies have investigated whether angiotensin II receptor blocker (ARB) is a practical
alternative to angiotensin-converting enzyme inhibitor (ACEI) for long-term use after acute …

Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …

The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Background In trials of patients with left ventricular dysfunction or heart failure, ACE inhibitor
use was unexpectedly associated with reduced myocardial infarction (MI). Using the Heart …

Treatment of acute myocardial infarction (MI) has been advanced considerably in the past
20 years with the advent of acute reperfusion strategies such as thrombolytic therapy or …

Objective: We evaluated the clinical efficacy of sacubitril/valsartan in a group of ambulatory
patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF …

Objectives: This study sought to assess the efficacy of angiotensin-converting enzyme
inhibitors (ACEIs) in patients with coronary heart disease and preserved left ventricular (LV) …

Patients with ST elevation myocardial infarction (STEMI) are at risk of future heart failure
(HF), particularly those with anterior STEMI. Interleukin-1 (IL-1) is a key mediator of the …